-
Diseases
Technologies
Themes / Divisions

About

My laboratory generates preclinical models of lung cancer and employs diverse disciplines such as molecular biology, clinical oncology, immunology and metabolomics to prioritise clinically relevant questions.

One major interest is the development of novel preclinical models that closely resemble human lung cancer. Genetic alterations found in human lung cancer patients can be replicated in our models using Cre-LoxP recombination and CRISPR/Cas9 technology. We also have the ability to direct cancer-associated mutations to specific lung epithelial cell populations, which enables us to interrogate potential cells-of-origin.

Through flow cytometric studies we have developed methods to interrogate the immune microenvironment of lung cancer. We are interested in understanding mechanisms of immunosurveillance with the aim of exploiting this knowledge to harness the immune system to treat lung cancer.

We are also interested in tumour heterogeneity and how this heterogeneity influences metastatic dissemination in lung cancer. We have developed sophisticated preclinical models that mimic the metastatic behaviour of the human disease. Current efforts are focused on testing novel treatment strategies to control cancer spread.

Publications

Selected publications from Prof Kate Sutherland

Ng J, Cai L, Girard L, Prall OWJ, Rajan N, Khoo C, Batrouney A, Byrne DJ, Boyd DK, Kersbergen AJ, Christie M, Minna JD, Burr ML, Sutherland KD. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clinical Cancer Research. 2024;30(9):10.1158/1078-0432.ccr-23-2360

Chen T, Lieschke E, Scott L, Boyd D, Sutherland K, Strasser A, Kelly G. Abstract LT06: Understanding the Role of Mutant TP53 in Lung Cancer Using Novel Genetically Engineered Mouse Models. Cancer Research. 2024;84(8_Supplement):10.1158/1538-7445.fcs2023-lt06

Ng J, Pan E, Johnston A, Ribera NT, Kersbergen A, Hess JB, Best SA, Tsui E, Steinfort D, Sutherland KD. A Multiplexed Approach to Assess Small Cell Lung Cancer Subtype Heterogeneity in Primary and Patient-Derived Tumor Samples. Methods in Molecular Biology. 2024;2806:10.1007/978-1-0716-3858-3_10

McDonald JA, Boyd D, Diepstraten S, Scott L, Tai L, Kueh A, Burr M, Best SA, Herold MJ, Sutherland KD. Abstract A043: Identifying critical vulnerabilities that sensitise Lkb1 -mutant lung adenocarcinoma to T cell mediated killing. Cancer Immunology Research. 2023;11(12_Supplement):10.1158/2326-6074.tumimm23-a043

Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends in Cancer. 2023;9(11):10.1016/j.trecan.2023.07.010

Weeden CE, Gayevskiy V, Marceaux C, Batey D, Tan T, Yokote K, Ribera NT, Clatch A, Christo S, Teh CE, Mitchell AJ, Trussart M, Rankin L, Obers A, McDonald JA, Sutherland KD, Sharma VJ, Starkey G, D’Costa R, Antippa P, Leong T, Steinfort D, Irving L, Swanton C, Gordon CL, Mackay LK, Speed TP, Gray DHD, Asselin-Labat M-L. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell. 2023;41(5):10.1016/j.ccell.2023.03.019

Wang Z, Hu H, Heitink L, Rogers K, You Y, Tan T, Suen CLW, Garnham A, Chen H, Lieschke E, Diepstraten ST, Chang C, Chen T, Moujalled D, Sutherland K, Lessene G, Sieber OM, Visvader J, Kelly GL, Strasser A. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death & Differentiation. 2023;30(4):10.1038/s41418-023-01122-3

Wang Z, Hu H, Heitink L, Rogers K, You Y, Tan T, Suen CLW, Garnham A, Chen H, Lieschke E, Diepstraten ST, Chang C, Chen T, Moujalled D, Sutherland K, Lessene G, Sieber OM, Visvader J, Kelly GL, Strasser A. Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death & Differentiation. 2023;30(4):10.1038/s41418-023-01137-w

Chen H, Nguyen NH, Magtoto CM, Cobbold SA, Bidgood GM, Guzman LGM, Richardson LW, Corbin J, Au AE, Lechtenberg BC, Feltham R, Sutherland KD, Grohmann C, Nicholson SE, Sleebs BE. Design and characterization of a heterobifunctional degrader of KEAP1. Redox Biology. 2023;59:10.1016/j.redox.2022.102552

Sparbier CE, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan KL, Bell CC, Gilan O, Chan Y-C, Popp S, Gough DJ, Eckersley-Maslin MA, Dawson S-J, Lehner PJ, Sutherland KD, Ernst P, McGeehan GM, Lam EYN, Burr ML, Dawson MA. Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes. Nature Cell Biology. 2023;25(2):10.1038/s41556-022-01056-x

Lab research projects

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.